TIDMHCM
RNS Number : 3134G
Hutchmed (China) Limited
23 July 2021
Stabilizing Actions and End of Stabilization Period in
connection with the Global Offering
Hong Kong, Shanghai & Florham Park, NJ - Friday, July 23,
2021: HUTCHMED (China) Limited ("HUTCHMED" or the "Company")
(Nasdaq/AIM: HCM; HKEX: 13) announces that the stabilization period
in connection with the Global Offering ended on July 23, 2021,
being the 30(th) day after the last day for the lodging of
applications under the Hong Kong Public Offering on June 23, 2021.
The stabilizing actions undertaken by Morgan Stanley Asia Limited,
as the Stabilizing Manager (or any person acting for it) during the
stabilization period were:
(1) over-allocations of an aggregate of 15,600,000 Offer Shares
in the International Offering, representing approximately 15% of
the total number of the Offer Shares initially available under the
Global Offering before any exercise of the Over-allotment
Option;
(2) borrowing of an aggregate of 15,600,000 Shares by Morgan
Stanley & Co. International plc (an affiliate of Morgan Stanley
Asia Limited) from Hutchison Healthcare Holdings Limited (an
indirect wholly-owned subsidiary of CK Hutchison Holdings Limited)
pursuant to the Stock Borrowing Agreement dated June 23, 2021, to
cover over-allocations in the International Offering; and
(3) the full exercise of the Over-allotment Option by the Joint
Global Coordinators, on behalf of the International Underwriters,
on July 12, 2021, in respect of an aggregate of 15,600,000 Offer
Shares, representing approximately 15% of the total number of the
Offer Shares initially available under the Global Offering before
any exercise of the Over-allotment Option, at the Offer Price, to
facilitate the return to Hutchison Healthcare Holdings Limited of
all the borrowed Shares under the Stock Borrowing Agreement which
were used to cover over-allocations in the International
Offering.
There has been no purchase or sale of any Shares on the market
for the purpose of price stabilization by the Stabilizing Manager
during the stabilization period.
For further details of the full exercise of the Over-allotment
Option, please refer to the HUTCHMED announcement dated July 12,
2021.
About HUTCHMED
HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative,
commercial-stage, biopharmaceutical company. It is committed to the
discovery and global development and commercialization of targeted
therapies and immunotherapies for the treatment of cancer and
immunological diseases. A dedicated organization of over 1,300
personnel has advanced eleven cancer drug candidates from in-house
discovery into clinical studies around the world, with its first
three oncology drugs now approved and marketed. For more
information, please visit: www.hutch-med.com or follow us on
LinkedIn.
Important Notice
Unless otherwise defined herein, capitalized terms used in this
announcement shall have the same meanings as those defined in the
prospectus dated Friday, June 18, 2021 (the "Prospectus") of
HUTCHMED.
This announcement is for information purposes only and does not
constitute an offer or an invitation to induce an offer by any
person to acquire, purchase or subscribe for any securities.
Potential investors should read the Prospectus for detailed
information about the Company and the Global Offering before
deciding whether or not to invest in the Offer Shares.
This announcement is not for release, publication, distribution,
directly or indirectly, in or into the United States (including its
territories and possessions, any state of the United States and the
District of Columbia) or to any U.S. person (as defined in
Regulation S under the U.S. Securities Act of 1933, as amended from
time to time, (the "U.S. Securities Act") or any other jurisdiction
where such distribution is prohibited by law. This announcement
does not constitute or form a part of any offer to sell or
solicitation to purchase or subscribe for securities in Hong Kong,
the United States or elsewhere. Securities may not be offered or
sold in the United States absent registration or an exemption from
registration under the U.S. Securities Act. Any public offering of
the Company's securities outside of the public offering in Hong
Kong will be made (i) pursuant to the shelf registration statement
on Form F-3ASR that was filed with the U.S. Securities and
Commission and became effective on April 6, 2020 and (ii) in
respect of securities to be sold to certain cornerstone investors,
in reliance on Rule 901 of Regulation S under the U.S. Securities
Act or pursuant to another exemption from the registration
requirements of the U.S. Securities Act, as described in the
section headed "Structure of the Global Offering - The
International Offering" in the Prospectus.
No prospectus required for the purposes of Regulation (EU)
2017/1129 ("EU Prospectus Regulation") or Regulation (EU) 2017/1129
(as it forms part of retained EU law as defined in the European
Union (Withdrawal) Act 2018) ("UK Prospectus Regulation") or
admission document (as defined in the AIM Rules for Companies
published by the London Stock Exchange plc) will be made available
in connection with the matters contained in this announcement. In
any member state of the European Economic Area, this announcement
is only addressed to and directed at qualified investors in that
member state as defined in article 2(e) of the EU Prospectus
Regulation.
This announcement, insofar as it constitutes an invitation or
inducement to enter into investment activity (within the meaning of
section 21 of the U.K. Financial Services and Markets Act 2000, as
amended) in connection with the securities which are the subject of
the Global Offering, is being directed only at (i) persons who are
outside the United Kingdom or (ii) if in the United Kingdom,
persons who are qualified investors as defined in article 2(e) of
the UK Prospectus Regulation who also (a) have professional
experience in matters relating to investments who fall within
Article 19(5) (investment professionals) of the U.K. Financial
Services and Markets Act 2000 (Financial Promotion) Order 2005, as
amended (the "Order") or (b) fall within Article 49(2)(a) to (d)
(high net worth companies, unincorporated associations etc.) of the
Order; or (iii) any other person to whom it may lawfully be
communicated (all such persons in (i) to (iii) together being
referred to as "specified persons"). This announcement is directed
only at specified persons and must not be acted on or relied on in
the United Kingdom by persons who are not specified persons. Any
investment or investment activity to which this announcement
relates is available only to specified persons and will be engaged
in only with specified persons.
CONTACTS
Investor Enquiries
Mark Lee, Senior Vice President +852 2121 8200
Annie Cheng, Vice President +1 (973) 567 3786
Media Enquiries
Americas - Brad Miles, +1 (917) 570 7340 (Mobile)
Solebury Trout bmiles@troutgroup.com
Europe - Ben Atwell / Alex Shaw, +44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile)
FTI Consulting HUTCHMED@fticonsulting.com
Asia - Joseph Chi Lo / Zhou Yi, +852 9850 5033 (Mobile) / +852 97 83 6894 (Mobile)
Brunswick HUTCHMED@brunswickgroup.com
Nominated Advisor
Atholl Tweedie / Freddy Crossley,
Panmure Gordon (UK) Limited +44 (20) 7886 2500
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
STAKZGZNGFKGMZM
(END) Dow Jones Newswires
July 23, 2021 07:01 ET (11:01 GMT)
Hutchison China Meditech (LSE:0J7G)
Graphique Historique de l'Action
De Jan 2025 à Fév 2025
Hutchison China Meditech (LSE:0J7G)
Graphique Historique de l'Action
De Fév 2024 à Fév 2025
